Switch theme
Sign up to access all valuation multiples
Jiangsu Hengrui Pharmaceuticals Co Ltd is engaged in the field of cancer treatment drugs, surgical medicines, endocrine therapy drugs, cardiovascular drugs and anti-infection medications. It specializes in the research and development of new medicines in areas of antineoplastics, endocrine system, cardiovascular, and the immune system.
1997
3.9K+
LTM Revenue $3.8B
LTM EBITDA $923M
$39.1B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Jiangsu Hengrui has a last 12-month revenue of $3.8B and a last 12-month EBITDA of $923M.
In the most recent fiscal year, Jiangsu Hengrui achieved revenue of $3.1B and an EBITDA of $738M.
Jiangsu Hengrui expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Jiangsu Hengrui valuation multiples based on analyst estimates| FY 2022 | FY 2023 | FY 2024 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $2.9B | $3.1B | $3.7B | $3.8B | XXX |
| Gross Profit | $3.0B | $2.4B | $2.6B | XXX | XXX |
| Gross Margin | 104% | 78% | 71% | XXX | XXX |
| EBITDA | $625M | $738M | $918M | $923M | XXX |
| EBITDA Margin | 21% | 24% | 25% | 25% | XXX |
| Net Profit | $622M | $536M | $591M | XXX | XXX |
| Net Margin | 21% | 17% | 16% | XXX | XXX |
| Net Debt | n/a | n/a | n/a | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of February 21, 2025, Jiangsu Hengrui's stock price is CNY 48 (or $7).
Jiangsu Hengrui has current market cap of CNY 308B (or $42.3B), and EV of CNY 285B (or $39.1B).
See Jiangsu Hengrui trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $39.1B | $42.3B | XXX | XXX | XXX | XXX | $0.13 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of February 21, 2025, Jiangsu Hengrui has market cap of $42.3B and EV of $39.1B.
Jiangsu Hengrui's trades at 10.4x LTM EV/Revenue multiple, and 42.4x LTM EBITDA.
Analysts estimate Jiangsu Hengrui's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Jiangsu Hengrui and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $39.1B | XXX | XXX | XXX |
| EV/Revenue | 10.6x | XXX | XXX | XXX |
| EV/EBITDA | 42.7x | XXX | XXX | XXX |
| P/E | 51.9x | XXX | XXX | XXX |
| P/E/Growth | 3.5x | XXX | XXX | XXX |
| EV/FCF | 70.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpJiangsu Hengrui's NTM/LTM revenue growth is 11%
Jiangsu Hengrui's revenue per employee for the last fiscal year averaged $0.8M, while opex per employee averaged $0.5M for the same period.
Over next 12 months, Jiangsu Hengrui's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Jiangsu Hengrui's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Jiangsu Hengrui and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 18% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 25% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 24% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 36% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.8M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.5M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 22% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 6% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 22% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 64% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Jiangsu Hengrui acquired XXX companies to date.
Last acquisition by Jiangsu Hengrui was XXXXXXXX, XXXXX XXXXX XXXXXX . Jiangsu Hengrui acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Jiangsu Hengrui founded? | Jiangsu Hengrui was founded in 1997. |
| Where is Jiangsu Hengrui headquartered? | Jiangsu Hengrui is headquartered in China. |
| How many employees does Jiangsu Hengrui have? | As of today, Jiangsu Hengrui has 3.9K+ employees. |
| Is Jiangsu Hengrui publicy listed? | Yes, Jiangsu Hengrui is a public company listed on SHG. |
| What is the stock symbol of Jiangsu Hengrui? | Jiangsu Hengrui trades under 600276 ticker. |
| When did Jiangsu Hengrui go public? | Jiangsu Hengrui went public in 2000. |
| Who are competitors of Jiangsu Hengrui? | Similar companies to Jiangsu Hengrui include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Jiangsu Hengrui? | Jiangsu Hengrui's current market cap is $42.3B |
| What is the current revenue of Jiangsu Hengrui? | Jiangsu Hengrui's last 12-month revenue is $3.8B. |
| What is the current EBITDA of Jiangsu Hengrui? | Jiangsu Hengrui's last 12-month EBITDA is $923M. |
| What is the current EV/Revenue multiple of Jiangsu Hengrui? | Current revenue multiple of Jiangsu Hengrui is 10.4x. |
| What is the current EV/EBITDA multiple of Jiangsu Hengrui? | Current EBITDA multiple of Jiangsu Hengrui is 42.4x. |
| What is the current revenue growth of Jiangsu Hengrui? | Jiangsu Hengrui revenue growth between 2023 and 2024 was 18%. |
| Is Jiangsu Hengrui profitable? | Yes, Jiangsu Hengrui is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
